Procter & Gamble Health Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
PGHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts more than Nifty Microcap 250 and 1.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Procter & Gamble Health has re-submitted its audited financial results for the 9-month period ended March 31, 2025, after changing its financial year-end from June 30 to March 31. Q4 revenue from operations rose about 23% year-on-year to Rs. 31,099 lakhs, while Q4 net profit jumped about 31% to Rs. 6,118 lakhs. For the full 9-month period, revenue grew nearly 8% to Rs. 93,417 lakhs and net profit rose about 27% to Rs. 23,441 lakhs. The board has recommended a final dividend of Rs. 45 per share (totalling about Rs. 7,469 lakhs), subject to shareholder approval. Statutory auditor Haribhakti & Co. LLP issued an unmodified (clean) opinion, and the company continues to be debt-free with healthy cash balances of Rs. 18,227 lakhs.
Strong double-digit growth in Q4 revenue and profit, combined with a healthy dividend, is likely to be viewed positively by shareholders. Year-on-year comparisons should be read with caution because the current period is a transitional 9-month financial year rather than a full 12 months.